风湿性心脏病二尖瓣修复与替换的长期结局比较
基于台湾全民健康保险研究数据库2000至2013年5086例风湿性心脏病二尖瓣手术成人患者,经倾向评分1:1匹配后每组467例。平均随访6年,修复组与替换组全因死亡风险相当(33.4% vs 32.5%;HR 1.01;95%CI 0.81-1.25),但修复组二尖瓣再手术风险更高(sHR 4.32;95%CI 2.02-9.23)。既往经皮经静脉二尖瓣交界分离术是修复组再手术的危险因素。
要点
- 风湿性心脏病二尖瓣修复与替换的远期全因死亡风险相当。
- 二尖瓣修复组再手术风险显著高于替换组(sHR 4.32)。
- 既往经皮经静脉二尖瓣交界分离术者修复后再手术风险更高。
核心结论
- 在风湿性心脏病患者中,二尖瓣修复与替换相比并未带来更优的长期结局。
- 因修复组再手术率更高,应仔细选择适合二尖瓣修复的患者,尤其是既往接受过经皮经静脉二尖瓣交界分离术者。
研究设计与样本
- 基于台湾全民健康保险研究数据库的回顾性队列研究,纳入2000至2013年接受二尖瓣修复或替换手术的成人风湿性心脏病患者。
- 共识别5086例患者,其中修复489例(9.6%)、替换4597例(90.4%);经1:1倾向评分匹配后每组467例。
- 平均随访6年。
主要发现
- 匹配后两组院内死亡风险无差异。
- 修复组与替换组全因死亡风险相当(33.4% vs 32.5%;HR 1.01;95%CI 0.81-1.25)。
- 修复组二尖瓣再手术风险更高(sHR 4.32;95%CI 2.02-9.23)。
- 既往经皮经静脉二尖瓣交界分离术被识别为修复组二尖瓣再手术的危险因素。
临床怎么用
- 风湿性心脏病二尖瓣手术决策时不应默认修复优于替换,需权衡再手术风险。
- 对既往接受过经皮经静脉二尖瓣交界分离术的患者,选择二尖瓣修复应格外谨慎。
局限性
- 原文摘要未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatic heart disease remains a major cause of cardiovascular death worldwide. Limited real-world nationwide data are available to compare the long-term outcomes between mitral valve repair and replacement in rheumatic heart disease. METHODS: We identified adult patients with rheumatic heart disease who underwent mitral valve repair or replacement surgery between 2000 and 2013 from Taiwan's National Health Insurance Research Database. Outcomes of interest included operation-related complications, all-cause mortality, and mitral valve reoperation rate. Propensity score matching at a 1:1 ratio was conducted to mitigate possible confounding factors. RESULTS: A total of 5086 patients with rheumatic heart disease who underwent mitral valve surgery were identified. Of those, 489 (9.6%) and 4597 (90.4%) underwent mitral valve repair and mitral valve replacement, respectively. After propensity score matching was applied, each group had 467 patients. No difference in risk of in-hospital mortality was observed between groups. With a mean follow-up of 6 years, the mitral valve repair group had comparable risks of all-cause mortality with the mitral valve replacement group (33.4% vs 32.5%; hazard ratio, 1.01; 95% confidence interval, 0.81-1.25). However, higher risks of mitral valve reoperation were observed in the mitral valve repair group (subdistribution hazard ratio, 4.32; 95% confidence interval, 2.02-9.23). Previous percutaneous transvenous mitral commissurotomy was identified as a risk factor of mitral valve reoperation in the repair group. CONCLUSIONS: Among patients with rheumatic heart disease, mitral valve repair is not associated with superior long-term outcomes. Patients should be carefully selected for mitral valve repair because of its higher reoperation rate, particularly those with previous percutaneous transvenous mitral commissurotomy.
引用
- Chen SW, Chen CY, Chien-Chia Wu V, et al. Mitral valve repair versus replacement in patients with rheumatic heart disease. J Thorac Cardiovasc Surg. 2020. PMID: 32994098. doi:10.1016/j.jtcvs.2020.07.117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。